Evidence map›Paper›PMID 34572870›Full record

ArticleCancers2021

Reproducibility of CT-Based Hepatocellular Carcinoma Radiomic Features across Different Contrast Imaging Phases: A Proof of Concept on SORAMIC Trial Data.

Abdalla Ibrahim, Yousif Widaatalla, Turkey Refaee, Sergey Primakov, Razvan L Miclea, Osman Öcal, Matthias P Fabritius, Michael Ingrisch, Jens Ricke, Roland Hustinx and 4 more

Abstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Abdalla IbrahimThe D-Lab, Department of Precision Medicine, GROW-School for Oncology, Maastricht University, 6200 MD Maastricht, The Netherlands.ORCID 0000-0003-4138-5755
Yousif WidaatallaThe D-Lab, Department of Precision Medicine, GROW-School for Oncology, Maastricht University, 6200 MD Maastricht, The Netherlands.
Turkey RefaeeThe D-Lab, Department of Precision Medicine, GROW-School for Oncology, Maastricht University, 6200 MD Maastricht, The Netherlands.ORCID 0000-0001-6605-1845
Sergey PrimakovThe D-Lab, Department of Precision Medicine, GROW-School for Oncology, Maastricht University, 6200 MD Maastricht, The Netherlands.
Razvan L MicleaDepartment of Radiology and Nuclear Medicine, Maastricht University Medical Centre+, 6200 MD Maastricht, The Netherlands.
Osman ÖcalDepartment of Radiology, University Hospital, LMU Munich, 80336 Munich, Germany.ORCID 0000-0001-5234-1921
Matthias P FabritiusDepartment of Radiology, University Hospital, LMU Munich, 80336 Munich, Germany.ORCID 0000-0002-3471-4701
Michael IngrischDepartment of Radiology, University Hospital, LMU Munich, 80336 Munich, Germany.
Jens RickeDepartment of Radiology, University Hospital, LMU Munich, 80336 Munich, Germany.
Roland HustinxDivision of Nuclear Medicine and Oncological Imaging, Department of Medical Physics, University Hospital of Liege and GIGA CRC-In Vivo Imaging, University of Liege, 4000 Liege, Belgium.
Felix M MottaghyDepartment of Radiology and Nuclear Medicine, Maastricht University Medical Centre+, 6200 MD Maastricht, The Netherlands.
Henry C WoodruffThe D-Lab, Department of Precision Medicine, GROW-School for Oncology, Maastricht University, 6200 MD Maastricht, The Netherlands.ORCID 0000-0001-7911-5123
Max SeidenstickerDepartment of Radiology, University Hospital, LMU Munich, 80336 Munich, Germany.
Philippe LambinThe D-Lab, Department of Precision Medicine, GROW-School for Oncology, Maastricht University, 6200 MD Maastricht, The Netherlands.ORCID 0000-0001-7961-0191

Funding

European Research Council ERC-ADG-2015 694812H2020 European Research Council 733008H2020 European Research Council 766276H2020 European Research Council 952013H2020 European Research Council 952172KWF Kankerbestrijding 12085/2018-2Maastricht-Liege Imaging Valley grant DEEP-NUCLETRANSCAN Joint Transnational Call 2016 UM 2017-8295
6 · The paper itself

Abstract

Handcrafted radiomic features (HRFs) are quantitative imaging features extracted from regions of interest on medical images which can be correlated with clinical outcomes and biologic characteristics. While HRFs have been used to train predictive and prognostic models, their reproducibility has been reported to be affected by variations in scan acquisition and reconstruction parameters, even within the same imaging vendor. In this work, we evaluated the reproducibility of HRFs across the arterial and portal venous phases of contrast-enhanced computed tomography images depicting hepatocellular carcinomas, as well as the potential of ComBat harmonization to correct for this difference. ComBat harmonization is a method based on Bayesian estimates that was developed for gene expression arrays, and has been investigated as a potential method for harmonizing HRFs. Our results show that the majority of HRFs are not reproducible between the arterial and portal venous imaging phases, yet a number of HRFs could be used interchangeably between those phases. Furthermore, ComBat harmonization increased the number of reproducible HRFs across both phases by 1%. Our results guide the pooling of arterial and venous phases from different patients in an effort to increase cohort size, as well as joint analysis of the phases.

Indexed as

CT radiomicsdomain translationhepatocellular carcinomareproducibility

Identifiers

PMID34572870
PMCPMC8468150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.